Pharmaceutical composition and its application in preparation of medicine for treating type II diabetes

Abstract

The invention relates a medicinal composition containing Gliquidone, taurine and its medicinal salts, and the use of the composition in preparing medicament for the treatment of diabetes, the treatment and / or prevention of renal disease complication related to type II diabetes. The composition comprises Gliquidone 10-180mg, taurine and its medicinal salts 0.5-10g, and pharmaceutically acceptable carrying agents.

Description

Technical field

[0001] The present invention relates to a pharmaceutical composition for the treatment of diabetes, more specifically, a pharmaceutical composition containing gliquidone and taurine, and the composition is prepared for the treatment of II diabetes, treatment and / or prevention Application of combined medicine for nephropathy complications related to type II diabetes. Background technique

[0002] Type II diabetes is due to genetic defects and a variety of acquired environmental factors that lead to insulin secretion defects and reduced insulin biological effects, which in turn causes a group of metabolic diseases characterized by hyperglycemia. Diabetes is the most harmful to human health due to various chronic complications based on arteriosclerosis and microvascular disease, such as diabetic nephropathy, diabetic heart disease, diabetic acral gangrene, diabetic cerebrovascular disease, and diabetic retinopathy And neuropathy, etc. Therefore, it often brings great...

Examples

Embodiment 1

[0047] A clinical comparative test between the combination product and gliquidone alone for the treatment of diabetes:

[0048] 1. The criteria for selection of patients are as follows: All diabetic patients meet the 1997 ADA / 1985 WHO diabetes diagnostic criteria, and 18 diabetic nephropathy (DN) patients are selected to match the rate of urinary protein, renal function and the development of renal function damage within 1 year. There was no significant difference between the two groups of patients in gender (male and female), age, course of diabetes, urine protein, urea nitrogen (BUN) and glycosylated hemoglobin (HbAlc) statistical test (P>0.05) (see table 1).

[0049] Group

example

Number

Age

Course of diabetes

(year)

Urine protein (g / L)

BUN

(mmol / L)

HbAlc(%)

Control

Group

8

54±

6.7

10.3±7.1

6.2±2.5

9.5±0.7

6.5±1.2

Treatment

Group

10

57± ...

Embodiment 2

[0072] Preparation of tablets:

[0073] A pharmaceutical composition containing 15g of gliquidone, 1058g of taurine sodium (equivalent to 900g of taurine), 100g of compressible starch, 25g of dextrin, 5g of microcrystalline cellulose, 2.5g of magnesium stearate, Mix uniformly, granulate with 40% ethanol, press tablets to make 1000 tablets, and coat them with film.

Technical field

[0001] The present invention relates to a pharmaceutical composition for the treatment of diabetes, more specifically, a pharmaceutical composition containing gliquidone and taurine, and the composition is prepared for the treatment of II diabetes, treatment and / or prevention Application of combined medicine for nephropathy complications related to type II diabetes. Background technique

[0002] Type II diabetes is due to genetic defects and a variety of acquired environmental factors that lead to insulin secretion defects and reduced insulin biological effects, which in turn causes a group of metabolic diseases characterized by hyperglycemia. Diabetes is the most harmful to human health due to various chronic complications based on arteriosclerosis and microvascular disease, such as diabetic nephropathy, diabetic heart disease, diabetic acral gangrene, diabetic cerebrovascular disease, and diabetic retinopathy And neuropathy, etc. Therefore, it often brings great...

Examples

Embodiment 1

[0047] A clinical comparative test between the combination product and gliquidone alone for the treatment of diabetes:

[0048] 1. The criteria for selection of patients are as follows: All diabetic patients meet the 1997 ADA / 1985 WHO diabetes diagnostic criteria, and 18 diabetic nephropathy (DN) patients are selected to match the rate of urinary protein, renal function and the development of renal function damage within 1 year. There was no significant difference between the two groups of patients in gender (male and female), age, course of diabetes, urine protein, urea nitrogen (BUN) and glycosylated hemoglobin (HbAlc) statistical test (P>0.05) (see table 1).

[0049] Group

example

Number

Age

Course of diabetes

(year)

Urine protein (g / L)

BUN

(mmol / L)

HbAlc(%)

Control

Group

8

54±

6.7

10.3±7.1

6.2±2.5

9.5±0.7

6.5±1.2

Treatment

Group

10

57± ...

Embodiment 2

[0072] Preparation of tablets:

[0073] A pharmaceutical composition containing 15g of gliquidone, 1058g of taurine sodium (equivalent to 900g of taurine), 100g of compressible starch, 25g of dextrin, 5g of microcrystalline cellulose, 2.5g of magnesium stearate, Mix uniformly, granulate with 40% ethanol, press tablets to make 1000 tablets, and coat them with film.